424 related articles for article (PubMed ID: 28084439)
1. De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.
Lopes MR; Pereira JK; de Melo Campos P; Machado-Neto JA; Traina F; Saad ST; Favaro P
Sci Rep; 2017 Jan; 7():40707. PubMed ID: 28084439
[TBL] [Abstract][Full Text] [Related]
2. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
Roversi FM; Cury NM; Lopes MR; Ferro KP; Machado-Neto JA; Alvarez MC; Dos Santos GP; Giardini Rosa R; Longhini AL; Duarte ADSS; Pericole FV; Favaro P; Yunes JA; Saad STO
J Cell Mol Med; 2019 Feb; 23(2):1562-1571. PubMed ID: 30484958
[TBL] [Abstract][Full Text] [Related]
5. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer L; Valent P; Greil R
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
[TBL] [Abstract][Full Text] [Related]
7. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
9. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network.
Carter BZ; Mak PY; Chen Y; Mak DH; Mu H; Jacamo R; Ruvolo V; Arold ST; Ladbury JE; Burks JK; Kornblau S; Andreeff M
Oncotarget; 2016 Apr; 7(15):20054-67. PubMed ID: 26956049
[TBL] [Abstract][Full Text] [Related]
10. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
[TBL] [Abstract][Full Text] [Related]
11. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia.
Kuett A; Rieger C; Perathoner D; Herold T; Wagner M; Sironi S; Sotlar K; Horny HP; Deniffel C; Drolle H; Fiegl M
Sci Rep; 2015 Dec; 5():18411. PubMed ID: 26674118
[TBL] [Abstract][Full Text] [Related]
12. Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.
Yokoyama K; Shimizu E; Yokoyama N; Nakamura S; Kasajima R; Ogawa M; Takei T; Ito M; Kobayashi A; Yamaguchi R; Imoto S; Miyano S; Tojo A
Blood Adv; 2018 Oct; 2(19):2513-2521. PubMed ID: 30282643
[TBL] [Abstract][Full Text] [Related]
13. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
14. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
[TBL] [Abstract][Full Text] [Related]
15. Alteration Analysis of Bone Marrow Mesenchymal Stromal Cells from De Novo Acute Myeloid Leukemia Patients at Diagnosis.
Desbourdes L; Javary J; Charbonnier T; Ishac N; Bourgeais J; Iltis A; Chomel JC; Turhan A; Guilloton F; Tarte K; Demattei MV; Ducrocq E; Rouleux-Bonnin F; Gyan E; Hérault O; Domenech J
Stem Cells Dev; 2017 May; 26(10):709-722. PubMed ID: 28394200
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
Geyh S; Rodríguez-Paredes M; Jäger P; Koch A; Bormann F; Gutekunst J; Zilkens C; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
Haematologica; 2018 Sep; 103(9):1462-1471. PubMed ID: 29773599
[TBL] [Abstract][Full Text] [Related]
17. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.
Wetzler M; Kurzrock R; Estrov Z; Estey E; Talpaz M
Leuk Res; 1995 Jan; 19(1):23-34. PubMed ID: 7837815
[TBL] [Abstract][Full Text] [Related]
18. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.
Zahid MF; Patnaik MM; Gangat N; Hashmi SK; Rizzieri DA
Eur J Haematol; 2016 Oct; 97(4):313-20. PubMed ID: 27147278
[TBL] [Abstract][Full Text] [Related]
19. SEMA3A partially reverses VEGF effects through binding to neuropilin-1.
Palodetto B; da Silva Santos Duarte A; Rodrigues Lopes M; Adolfo Corrocher F; Roversi FM; Soares Niemann F; Priscila Vieira Ferro K; Leda Figueiredo Longhini A; Melo Campos P; Favaro P; Teresinha Olalla Saad S
Stem Cell Res; 2017 Jul; 22():70-78. PubMed ID: 28636974
[TBL] [Abstract][Full Text] [Related]
20. Focal Adhesion Kinase as a Potential Target in AML and MDS.
Carter BZ; Mak PY; Wang X; Yang H; Garcia-Manero G; Mak DH; Mu H; Ruvolo VR; Qiu Y; Coombes K; Zhang N; Ragon B; Weaver DT; Pachter JA; Kornblau S; Andreeff M
Mol Cancer Ther; 2017 Jun; 16(6):1133-1144. PubMed ID: 28270436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]